Cannabis Report
Home > Boards > US OTC > Medical - Healthcare >

Theralase Technologies Inc. (TLTFF)

Add TLTFF Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 6/11/2018 7:42:47 PM - Followers: 76 - Board type: Free - Posts Today: 0


Jan 22, 2014 7:20 AM | about stocks: TLTFF


Theralase Technologies Inc. (TSX-V: TLT, US-OTCBB: TLTFF). They design, develop, manufacture and market, patented, super-pulsed laser technology used in biostimulative and biodestructive clinical applications. The Theralase technology platform targets several health-care sectors: First, for non-invasive pain management and clinical therapy, used in neural muscular skeletal conditions, including arthritis and osteoarthritis; Second, wound care and healing (including non-healing fractures and bone fracture regeneration); And third, research and development into combining patented photodynamic compounds (PDCs) with patented, super-pulsed, biofeedback laser technology to attack specifically targeted cancers, bacteria and viruses.

The company is currently focused on the commercialization (production, marketing and distribution) of the TLC-2000 Superpulsed Laser Technology to healthcare practitioners, and commercialization of the patented TLC-3000 Photo Dynamic Compound Cancer Technology through pre-clinical research and clinical trials.

Key Investment Highlights:

  • Working on breakthrough bladder cancer destruction technology and has achieved tremendous success in pre-clinical trials
    Proven clinical technology (TLC-1000) and commercial therapeutic laser business and brand developed over last 17 years, currently generating ~2M of revenue annually
    Rollout of new TLC-2000 technology in 2014, along with a new recurring revenue business model
    Strategic agreements in place with world renowned institutions to help advance research and mitigate expenses
    Competitive technical advantages (Cellular pathways: iNOS, ATP, Na+ / K+)
    Future technology (patented biofeedback technology and patented PDC cancer destruction)
    IP protection (multiple issued patents)
    Large addressable US markets ($ billions)
    No debt
    Positive cash flow / double digit growth
    Lots of opportunity for short-term and long-term growth (revenue & profit)
    Experienced management team (20+ years)
    Clear vision and execution strategy


Theralase has patented anti-cancer drugs known as Photo Dynamic Compounds (PDCs) which localize the DNA of cancer cells and when irradiated, destroy the DNA resulting in apoptosis (natural cell death). While PDCs are used in Photodynamic Therapy (PDT) as a potential treatment regime for a number of conditions, Theralase has discovered that they hold particular promise as treatment to particular cancers. Theralase PDCs have proven successful in destroying breast, colon, brain and bladder cancer cells. Recent lab results have shown that Theralase was able to completely destroy subcutaneous bladder cancer tumors in mouse models. "The achievement of this important milestone signifies that Theralase's leading drug candidate is effective in the destruction of cancer in a live animal model and can prevent the cancer from recurring," commented Roger White of Theralase.

Key Market Statistics:

  • US bladder cancer treatment annual spending was $3.9 billion in 2012
    70,000 new cases, > 14,000 deaths in the US each year
    386,000 new cases are diagnosed worldwide annually
    Standard treatment unchanged with no new drugs approved since 1998
    5th most common cancer, 4th in men, 8th in women
    Most expensive cancer to treat with a recurrence rate up to 80%
    70% of new bladder cancer cases are early stage disease and 90% of bladder cancers are Transitional Cell Carcinoma (TCC)

Theralase PDC Characteristics:

  • Up to 100% cancer cell kill at very low concentrations (< 0.8μM)

(click to enlarge)

  • More effective at killing cancer cells than FDA approved drugs

(668,000x ALA, 198x PHOTOFRIN)

  • Survival of mice up to 20 months (50 human years) after one Theralase PDT treatment

(click to enlarge)

We are VERY IMPRESSED, and VERY EXCITED about these results! In 2012, annual spending for bladder cancer treatment in the US was $3.9 billion, and the current standard of care has been unchanged with no new drugs approved since 1998. Bladder cancer is the most expensive cancer to treat, and has a recurrence rate up to 80%. All of the mice which showed an initial response have remained cancer free, healed without scarring, and have developed normally after only one Theralase PDC treatment. Needless to say, the early results from Theralase look extremely positive. Imagine being able to not only provide treatment for bladder cancer, but to actually cure it, and stop it from coming back! The company is also working on developing further PDCs that can be used to treat a wide variety of other cancers (breast, colon, brain and lung), as well as bacteria and viruses.

  • The general patent protects 1,000s of molecules - essentially a library of PDCs
    Virtually 0% toxicity at high concentrations (> 100μM) leading to ultra-high safety profile
    Activated by laser light providing excellent specificity and selectivity
    Able to treat solid core hypoxic tumors, such as: breast, prostate and lung
    Research outsourced to and performed at world renowned Princess Margaret Cancer Centre
    Patented under numerous US and International Patents:
    Issued USA Patents: 6,962,910, 7,612,057, 8,148,360, 8,445,475
    Pending USA Patent Applications: 61/801,674, 13/863,089, 13/36595

To help explain how the procedure works we sketched a diagram:

(click to enlarge)

  1. A catheter is inserted into the patient
    The PDC is injected and saturates within the patient's bladder, penetrating the cellular membrane (DNA localizing)
    Fiber optics cables are inserted up the catheter into the bladder
    Using laser technology, light is irradiated 360°
    The entire procedure takes about 2 - 3 hours

Theralase is currently completing the validation of the orthotopic rat model, a dose toxicity study, GMP drug manufacture, and FDA Investigational New Drug (IND) application. The next phase is to complete an FDA phase 1/2a human clinical study with FDA breakthrough status, and then to execute a strategic partnership agreement with big pharmaceutical (pharma) company (upfront payments, co-development funds, annual recurring revenue streams).

Industry comparables:

(click to enlarge)

(click to enlarge)

Deals with comparable big pharma companies have yielded anywhere from $466M to $1B plus royalties.


The thing is, by the time clinical trials have been completed (assuming they're successful), Theralase will be trading many multiples higher than today. Look how excited investors got when Theralase first released PDC breast cancer results during January 2010, the intraday high for TLT was $1.39/share:

Read More :

Themes: Biotechnology, Micro Capitalization, Growth Opportunity, Pharmaceuticals, Cancer, Laser Technology, Photo Dynamic Compounds (PDCs) Stocks: TLTFF
Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TLTFF News: Small Company Offering and Sale of Securities Without Registration (d) 05/29/2018 05:28:56 PM
TLTFF News: Theralase Demonstrates 18 Month Stability of Lead Anti-Cancer Drug 03/15/2017 07:02:00 AM
TLTFF News: Theralase Anti-Cancer Technology Picks Up Steam 01/06/2015 07:00:00 AM
TLTFF News: Theralase CEO to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM 03/12/2014 07:05:00 AM
TLTFF News: Theralase Achieves Commercialization Milestone For Its Bladder Cancer Therapy 03/14/2013 07:00:04 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#3326   I read more of the original "Theralase® Demonstrates scoobey-do 06/11/18 07:42:47 PM
#3325   Agree. What is encouraging to me is Hank Kerchief 06/11/18 11:19:48 AM
#3324   Hank it is like the first steel boat -3 06/11/18 11:15:54 AM
#3323   If the animal studies translate to human studies Hank Kerchief 06/11/18 10:41:49 AM
#3322   Can look at rev projections for NMIBC refractory 123414 06/11/18 10:25:47 AM
#3321   Speculative Buy $0.90 Target 123414 06/11/18 10:22:28 AM
#3320   So TLT is a little over 30 cents Hank Kerchief 06/11/18 10:20:52 AM
#3319   Yes and the rat studies are not part 123414 06/11/18 10:16:50 AM
#3318   This is amazing considering that only 2% of Hank Kerchief 06/11/18 10:08:02 AM
#3317   Theralase® Demonstrates Significant Advantage in Treatment of Brain Tumours 123414 06/11/18 09:06:16 AM
#3316   Tlt for 10x. Can't have results MIKE22CA 06/08/18 03:56:05 PM
#3315   This stock may rise on lower volume for 123414 06/08/18 10:48:17 AM
#3314   Speculative Buy $0.90 Target 123414 06/08/18 10:38:34 AM
#3313   They have to be thru phase 1 to Luckysevens 06/07/18 08:32:45 PM
#3312   ...also realize we follow ICH/GCP guidelines for clinical Geo2014 06/07/18 05:40:46 PM
#3311   That is new territory for all of us. Geo2014 06/07/18 05:37:07 PM
#3310   With your work as a Clinical Research Associate, scoobey-do 06/07/18 04:44:35 PM
#3309   Well there is more to predicting price than 123414 06/07/18 03:14:32 PM
#3308   Nah. Unfortunately this price is propped up. bababooyah 06/07/18 03:11:43 PM
#3307   This chart is rangebound goin back to about 123414 06/07/18 03:05:25 PM
#3306   My charts point to lower and lower prices. bababooyah 06/07/18 01:48:01 PM
#3305   Thanks CUIN! And thanks for the info Geo2014 06/07/18 12:59:32 PM
#3304   This is a fair assessment based on your CUIN2 06/07/18 12:49:33 PM
#3303   Well, if you look back at the history Geo2014 06/07/18 12:26:45 PM
#3302   Speculative Buy $0.90 Target 123414 06/07/18 11:07:11 AM
#3301   Theralase Demonstrates 36 Months Stability of Lead Anti-Cancer Drug 123414 06/06/18 02:16:46 PM
#3300   Theralase Sustains IP Strength with Newly Issued US 123414 06/05/18 05:10:40 PM
#3299   This company has missed timelines consistently though . -3 06/05/18 12:24:16 PM
#3298   This poster thinks the time lines will be -3 06/05/18 08:28:02 AM
#3297   We describe TLD-1433 clinical timelines embedded in our 123414 06/05/18 07:54:49 AM
#3296   Touche' You're right. Geo2014 06/05/18 07:11:18 AM
#3295   FUSZ is over, look at the chart lmao Luckysevens 06/04/18 10:30:55 PM
#3294   Ya shouldn’t call others pumpers when you yourself MasterSalix 06/04/18 06:14:04 PM
#3293   I'll take my chances. If TLTFF is Geo2014 06/04/18 04:38:48 PM
#3292   If you waited till then you could be 123414 06/04/18 04:30:44 PM
#3291   Sure, if you want to tie up your Geo2014 06/04/18 04:26:01 PM
#3290   As the milestones get met we should have 123414 06/04/18 04:25:02 PM
#3289   Yep, just following your lead. You are Geo2014 06/04/18 04:22:41 PM
#3288   Now is the time for accumulation. Cheers! 123414 06/04/18 04:21:00 PM
#3287   Isn't that completely obvious? The warrants and options 123414 06/04/18 04:19:15 PM
#3286   Minimum 4 years away... no point Geo2014 06/04/18 04:15:56 PM
#3285   Phase II gets more expensive since more subjects Geo2014 06/04/18 04:12:36 PM
#3284   Slowed burn rate and milestones completed. 123414 06/04/18 03:50:59 PM
#3283   We describe TLD-1433 clinical timelines embedded in our 123414 06/04/18 09:44:24 AM
#3282   that was for the first 3 only.. just MIKE22CA 06/04/18 08:43:50 AM
#3281   Speculative Buy $0.90 Target 123414 06/02/18 07:14:10 AM
#3280   President Donald Trump Signs Right To Try Act 123414 06/01/18 03:19:57 PM
#3279   123414 06/01/18 01:54:57 PM
#3278   OK ‘cancer free’ Luckysevens 05/31/18 11:53:32 AM
#3277   The Phase I results are promising but please Geo2014 05/31/18 11:49:13 AM